ED-580XT in Clinical Studies

Published in Gastrointestinal Endoscopy, Vol. 91, Issue 6, AB67–AB68:

Cost Utility Analysis Comparing Duodenoscope Reprocessing/Sterilization, Novel Duodenoscopes with Disposable Endcaps and Fully Disposable Duodenoscopes

Author(s): Monique Barakat*² , Swarnadip Ghosh² , Subhas Banerjee¹ 1 Stanford University Medical Center Division of Gastroenterology & Hepatology, Stanford, CA 2 Stanford University Department of Statistics, Stanford, CA Abstract # 775 from DDW[®] 2020

Background: Transmission of multi-drug resistant organisms by duodenoscopes used during ERCP is problematical. The FDA (Food & Drug Administration) recently issued a communique recommending transition away from reusable fixed endcap duodenoscopes to those with newer design features that facilitate or eliminate the need for reprocessing. Duodenoscopes with disposable endcap and fully disposable duodenoscopes have now been developed. This analysis evaluates the relative cost of different approaches to minimizing infection risk, taking into account the cost associated with duodenoscope-transmitted infection.

Methods: We developed a Monte Carlo analysis model in R to assess the cost-effectiveness of various approaches: (1) Single High Level Disinfection (HLD), (2) Double HLD, (3) Ethylene oxide (EtO) sterilization, (4) Culture & hold, (5) Duodenoscope with disposable endcap and (6) Disposable duodenoscope. This model utilizes a multi-state trial framework and institutional cost estimates (Table 1). We assumed a triangular distribution with 3 parameters: minimum, maximum and most probable infection rate (MPIR), which vary across the six options. Using these values, we simulated quality adjusted life years (QALY) lost by duodenoscope-transmitted infection and factored this into the average cost for each approach. Our model's simulated cost for each approach at variable rates of MPIR is depicted in Figure 1.

Results: At all rates of infection transmission below 1%, the duodenoscope with disposable endcap was the most cost-effective approach (Figure 1). The fully disposable duodenoscope eliminates the potential for infection transmission and is more cost effective than single/double HLD at all infection transmission rates, more cost effective than EtO for MPIR <0.22%, and more cost effective than culture & hold for MPIR <0.49%. Single and double HLD are the two most costly approaches at all potential infection transmission rates. The next two most costly approaches: EtO and culture & hold, require more duodenoscopes and costly transport/institutional infrastructure.

Conclusions: Our model indicates that novel duodenoscopes with a disposable endcap represent the most cost-effective option performing ERCP, with an anticipated very low infection transmission rate and disposable element costing approximately 1/5 that of the fully disposable duodenoscope. Limitations of this model include necessary assumptions and the potential lack of generalizability to lower volume community facilities. These data underscore the importance of cost calculations which account for the potential for infection transmission and associated patient morbidity/mortality associated with each approach. Institution-specific cost analyses will become increasingly relevant as the FDA recommendation for transitioning to duodenoscopes with newer design features gains momentum.

To read the abstract, visit: https://www.giejournal.org/article/S0016-5107(20)30839-7/fulltext

| Duodenoscope-transmitted infection minimization approach | Estimated 'Per Use' Cost (Materials & Labor) | Infection Transmissi (Estimated Range) | on Rate | # Reusable Duodenoscopes Needed |
|---|---|--|--|--------------------------------------|
| Single Reprocessing | 130.92 | 0.1-5% | | 5 |
| Double Reprocessing | 188.32 | 0.1-3% | | 7 |
| EtO | 643.68 | 0.1-2% | | 12 |
| Culture & Hold | 386.67 | 0.1-2% | | 12 |
| Disposable Endcap | 654.00 | 0.1-1% | | 5 |
| Disposable Duodenoscope | 2,903.50 | 0% | | 0 |
| Model Assumptions & Justific Parameter/Assumption | ation | Value | Basis for | Assumption/Value |
| Annual ERCP Volume | | 800 | Annual ERC | P volume at our tertiary care center |
| Tertiary Care Overall MDRO Infection Carrier/Infection Rate | | 11% | Derived from tertiary care infection control data. | |
| MDRO Transmission Rate after ERCP performed with MDRO-infected duodenoscope | | e 30% | Infectious disease consultation/literature based. | |
| Rate of Clinical Symptom Development in MDRO Infected Patient | | 50% | Infectious disease consultation/literature based. | |
| Cost of management of cholangitis (2-day ICU stay, 1 day stepdown) | | \$375,000 | Derived from our tertiary care center. | |
| Rate of Survival after MDRO Infection | | 70% | Infectious disease consultation/literature based. | |
| Average Age of Patients undergoing ERCP | | 60 (range 18-99) | Derived from our tertiary care center data. | |
| Estimated Post-ERCP Lifespan | | 7 years | Derived from our tertiary care center data. | |
| Value of Quality Adjusted Life Years | | \$100,000/year | Standard value within accepted QALY range. | |



WHY IT'S RELEVANT

There is much concern o er the challenges associated with ro erly cleaning duodenosco es and the risks $[-] [-\hat{a}|^{\hat{a}} \hat{O} = \hat{O}$

Key Takeaways:

- 1. This study indicates that Duodenoscopes with disposable endcaps are more cost effective than fully disposable duodenoscopes up to a most probable infection transmission rate of 1%.
- 2. Facilities are encouraged to assess their duodenoscope and reprocessing methods to identify underlying risk and costs associated with their current practice as well as anticipated changes to their practice.

Digestive Disease Week[®] (DDW[®]) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), the meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

DDW Administration had no influence on the selection of the abstracts and/or content included in this event. DDW LLC shall not be liable for any direct, indirect, punitive, consequential, or other damages in any way arising or resulting from the Event or the use of information or materials from DDW sessions by any institution. Should any claim or suit be brought against DDW LLC arising from an Event, the institution shall indemnify and hold DDW LLC harmless for any damages, liability, and costs, including attorney fees, suffered or incurred by DDW LLC in defense and satisfaction thereof.

